Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy

Bijay Singh; Shicheng Yang; Apurva Krishna; Srinivas Sridhar

doi:10.3389/fchem.2020.594619

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy

Front Chem. 2020 Nov 23:8:594619. doi: 10.3389/fchem.2020.594619. eCollection 2020.

Authors

Bijay Singh^{1

2}, Shicheng Yang^{1

3}, Apurva Krishna^{1

4}, Srinivas Sridhar^{1

2

3

4

5}

Affiliations

¹ Nanomedicine Innovation Center, Northeastern University, Boston, MA, United States.
² Department of Physics, Northeastern University, Boston, MA, United States.
³ Department of Chemical Engineering, Northeastern University, Boston, MA, United States.
⁴ Department of Bioengineering, Northeastern University, Boston, MA, United States.
⁵ Department of Radiation Oncology, Harvard Medical School, Boston, MA, United States.

Abstract

A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged administration of these inhibitors indicate the need for improved methods of drug delivery to the tumors. Nanomedicines based upon nanoparticle formulations of conventional small molecule drugs and inhibitors offer many advantages, such as increased solubility and bioavailability of drugs, reduced toxicity and drug resistance, and improved tissue selectivity and therapeutic efficacy. This review highlights the current trends in formulations of PARP inhibitors developed by nanotechnology approaches and provides an insight into the applications and limitations of these PARP inhibitor nanomedicines for cancer therapies.

Keywords: Cancer therapy; PARP inhibitor; nanomedicine; nanoparticle; poly(ADP-ribose) polymerase (PARP).

Publication types

Review